Opus Genetics, Inc.
NASDAQ:IRDBiotechnology
-$0.01 today
- Market cap
- $326.13M
- Beta
- 0.55
- P/E (TTM)
- -33.0
- EPS (TTM)
- -$0.12
Volume 0.75M
Average 0.81M
IRD Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Opus Genetics, Inc.NASDAQ: IRD
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow grows, but more slowly than its trailing trend
Q1 FY2026 financing cash flow of $27.6M rose 34.8% year over year, behind the +156.6% change in trailing-twelve-month financing cash flow. Sequentially, it rose 14.5% from the prior quarter. Over 3 fiscal years it compounded at +136.4% a year.
Context
- Financing cash flow amounted to 352.4% of revenue in FY2025, up 314.3 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +34.8% toward the trailing-twelve-month pace of +156.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 50.02M USD
- Year-over-year change
- +1095.0%
- 4-year CAGR
- +16.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 50.02M | +1095.0% |
| FY2024 | 2024-12-31 | 4.19M | -53.4% |
| FY2023 | 2023-12-31 | 8.98M | +137.2% |
| FY2022 | 2022-12-31 | 3.79M | -86.3% |
| FY2021 | 2021-12-31 | 27.61M | — |
Financing Cash Flow vs competitors
How IRD compares with its peers on the latest reported figures
- IRD's LTM Mar 2026 financing cash flow of $57.15M is the largest of the 10 companies compared; the peer median is $27.62M.
- Its year-over-year change of +156.6% is the 4th highest of 9, against a peer median of +103.1%.
- Financing cash flow amounts to 477.0% of revenue for IRD, versus a peer median of 93.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
IRDOpus Genetics, Inc. | LTM Mar 2026 | $57.15M | +156.6% | +136.4% | 477.0% |
| LTM Mar 2026 | $52.98M | -17.1% | -13.5% | — | |
| LTM Mar 2026 | $35.74M | +16725.1% | — | — | |
| LTM Mar 2026 | $35.04M | +172.3% | +87.5% | — | |
| LTM Mar 2026 | $32.01M | -71.3% | +8.6% | 25.8% | |
| LTM Mar 2026 | $27.62M | — | +7.0% | — | |
| LTM Mar 2026 | $20.24M | +94.0% | +64.8% | 109.9% | |
| LTM Mar 2026 | $13.15M | +112.2% | -52.5% | 1146.1% | |
| LTM Mar 2026 | $11.67M | -10.2% | — | 77.6% | |
| LTM Mar 2026 | $7.06M | +255.3% | -53.4% | — | |
| Peer median (excluding IRD) | $27.62M | +103.1% | +7.0% | 93.8% | |
Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (56.69M) | 17.89M | (9.99M) | (57.53M) | (49.59M) |
| Depreciation & Amortization | 4K | 4K | 6K | 10K | 53K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.91M | 1.81M | 3.51M | 3.36M | 3.4M |
| Change in Working Capital | 181K | (5.56M) | 4.08M | 3.09M | (2.15M) |
| Accounts Receivables | 0 | (4.85M) | 2.52M | (3.44M) | 2.61M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 381K | (515K) | 1.08M | 220K | 7K |
| Other Working Capital | (200K) | (190K) | 477K | 6.31M | (4.77M) |
| Other Non-Cash Items | 35.22M | 170K | 1.28M | 25.49M | 13.04M |
| Operating Cash Flow | (19.37M) | 14.31M | (1.11M) | (25.58M) | (35.25M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (100K) | 0 | 0 | 1.21M | 0 |
| Investing Cash Flow | (100K) | 0 | 0 | 1.21M | 0 |
| Debt Repayment | 538K | (538K) | 0 | 0 | 1M |
| Common Stock Issued | 28.49M | 4.43M | 9.23M | 4.5M | 49.18M |
| Common Stock Repurchased | 0 | 0 | 0 | (79K) | (152K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.42M) | (104K) | (248K) | (232K) | 0 |
| Financing Cash Flow | 27.61M | 3.79M | 8.98M | 4.19M | 50.02M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 8.14M | 18.1M | 7.87M | (20.18M) | 14.77M |
| Free Cash Flow | (19.37M) | 14.31M | (1.11M) | (25.58M) | (35.25M) |
Opus Genetics, Inc.
NASDAQ:IRD
Intrinsic Alpha fair value
Locked
Current Price
$3.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.